GH Dec 2023 50.000 put
| Previous close | 20.80 |
| Open | 21.10 |
| Bid | 24.10 |
| Ask | 27.00 |
| Strike | 50.00 |
| Expiry date | 2023-12-15 |
| Day's range | 20.80 - 21.10 |
| Contract range | N/A |
| Volume | |
| Open interest | 270 |
Business WireGuardant Health to present data at San Antonio Breast Cancer Symposium demonstrating utility of liquid biopsy in biomarker identification, therapy selection and residual disease detection
PALO ALTO, Calif., November 30, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present data showing the utility of liquid biopsy tests in the management of breast cancer patients at the San Antonio Breast Cancer Symposium, December 5-9 in San Antonio, Texas. Highlights of the eight poster presentations include the use of blood-based testing to identify actionable biomarkers and predict therapy response in advanced breast cancer, and to detect residual diseas
- Business Wire
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., November 15, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on November 8, 2023, the Compensation Committee of Guardant’s Board of Directors granted restricted stock units ("RSUs") representing 50,741 shares of its common stock to 43 new non-executive employees under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the "Inducement Plan"). The RSUs were granted as inducements material to the employe
- Business Wire
Guardant Health to Appeal Federal District Court Verdict
PALO ALTO, Calif., November 15, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it intends to appeal yesterday’s verdict in the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington.
